Researcher Jamil Chade & colleagues (Brazil) shared their experience using Cyclosporine A as a treatment for IC. They enrolled 36 patients in their study, who received 1.5 mg/kg of cyclosporine A, twice a day, for 12 months. The patients were re-evaluated for the symptoms (ICSI) and by urodynamics at 6 and 12 months of treatment.
The results showed a decrease in IC symptoms, as well as an increase in bladder capacity. All the patients had biochemical analysis before and after the treatment, and no abnormalities were found for liver and renal function.
The authors concluded "Considering the treatment of IC, cyclosporine A represents a new alternative. The good tolerance, safety, and promising results recommend the use of cyclosporine A for the treatment of IC."
--------------
Source: AUA Abstract [121] EVALUATION OF SYMPTOMS IN PATIENTS WITH INTERSTITIAL CYSTITIS TREATED WITH CYCLOSPORINE A
Jamil Chade, MD, Antonio M Lucon, MD, Daher C Chade, MD, Miguel Srougi, MD, PhD. University of São Paulo, São Paulo, Brazil
The results showed a decrease in IC symptoms, as well as an increase in bladder capacity. All the patients had biochemical analysis before and after the treatment, and no abnormalities were found for liver and renal function.
The authors concluded "Considering the treatment of IC, cyclosporine A represents a new alternative. The good tolerance, safety, and promising results recommend the use of cyclosporine A for the treatment of IC."
--------------
Source: AUA Abstract [121] EVALUATION OF SYMPTOMS IN PATIENTS WITH INTERSTITIAL CYSTITIS TREATED WITH CYCLOSPORINE A
Jamil Chade, MD, Antonio M Lucon, MD, Daher C Chade, MD, Miguel Srougi, MD, PhD. University of São Paulo, São Paulo, Brazil
Comment